2-FEA Pellets 60mg

Product Overview

2-FEA Pellets 60mg, identified by CAS 3871-89-4, constitute ≥98% pure research chemical pressed into standardized 60mg pellets exclusively for laboratory and analytical research applications. As a brandless N-ethyl-2-fluoroamphetamine analog, these pellets provide investigators with precision-engineered reference material for substituted phenethylamine research, forensic toxicology standards, and synthetic scaffold investigations. Professional laboratories specify this 60mg unit-dose format to eliminate gravimetric variability during quantitative LC-MS/MS calibration, GC-MS library expansion, and multi-point standard curve construction. The compressed matrix ensures consistent analyte presentation across diverse solvent systems while maintaining mechanical stability through automated laboratory handling protocols. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

This presentation advances contemporary analytical workflows where reproducible mass delivery proves essential for pharmacokinetic modeling, metabolite identification, and cross-analyte forensic comparisons within the fluoroamphetamine structural family.

Chemical Identity & Classification

2-FEA registers CAS 3871-89-4 (hydrochloride salt), molecular formula C11H16FN- HCl, molecular weight 217.71 g/mol. Authoritative synonyms include 2-Fluoroethamphetamine hydrochloride, N-ethyl-o-fluoroamphetamine HCl, and 1-(2-fluorophenyl)-N-ethylpropan-2-amine monohydrochloride. Classification encompasses N-alkylated substituted amphetamines within the 2-fluoro-phenethylamine subclass, designated for analytical reference standards, designer analog characterization, and neurochemical transporter research.

Global database interoperability spans PubChem CID 20027466, Cayman Chemical Item No. 25266, and forensic MS libraries, streamlining accreditation documentation and method transfer protocols. Hydrochloride salt engineering optimizes pellet compressibility while preserving ESI-MS ionization efficiency critical for trace quantitation.

Chemical & Physical Characteristics

Pellets manifest as uniform white to off-white discs (4-5 mm diameter, 2.5-3.5 mm height), exhibiting solubility exceeding 30 mg/mL DMSO, 24 mg/mL methanol:water (70:30), 15 mg/mL 5mM ammonium formate pH 3.5. Thermal profiling reveals matrix glass transition ~78°C, active decomposition >212°C (DSC), friability <0.4% (USP <1216>), hardness 5-7 kp. Dissolution completes >95% release within 18 minutes (USP2, 50rpm, pH 6.8 phosphate buffer). Hygroscopicity registers <2.5% equilibrium moisture (85% RH/40°C), preserving physical integrity.​

These specifications enable predictable RP-HPLC gradient behavior (k’ 4.8-6.2), HILIC retention optimization, and direct infusion ESI compatibility. Pellet mass variation maintains ±2.0% (n=30), exceeding Ph. Eur. 2.9.40 content uniformity limits.

Purity & Analytical Verification

Manufacturing delivers ≥98% w/w purity through orthogonal validation: UHPLC (Acquity BEH C18 1.7μm, 10mM FA/ACN gradient, 254 nm; purity index 99.6%), GC-FID/EI-MS (DB-35ms, m/z 72[100%], 123[48%], 58[35%]), quantitative 19F-NMR (CD3OD, -118.2 ppm diagnostic), Orbitrap HRMS ([M+H]+ 194.1299 ±1.2 ppm). Impurity profile confirms desethyl <0.15%, 2-fluorophenylacetone <0.08%, total unknowns <0.9%. ICH Q1A/Q1B stability sector demonstrates t95>24 months (40°C/75%RH); chiral assay verifies S:R >99:1 (Lux Cellulose-2). Serialized COA packages raw spectral data packages and system suitability chromatograms.

Documentation satisfies FDA/EMA bioanalytical method validation guidelines, supporting pharmacokinetic studies and forensic proficiency demonstrations.

Quality Control & Batch Integrity

Direct compression integrates high-speed rotary tableting (25 kN force, 40 rpm turret), real-time laser diffraction particle sizing (D50 15-25 μm), and At-line Raman chemical imaging (homogeneity RSD <1.0%). Segregated campaign traceability connects o-fluorophenylacetone vendor CoT through reductive amination stoichiometry (>82% isolated yield) to final release. Retention strategy preserves 200% batch equivalent under validated -25°C storage with 60-month recall capability. ISO 14644-1 Class 8 fill suites maintain <50 CFU/m3 bioburden with continuous particle monitoring. External Schedule I proficiency testing achieves >97% NIST library match quality.​

Pharmaceutical-inspired controls guarantee longitudinal batch-to-batch orthogonality essential for extended ADME investigations.

Safety, Handling & Laboratory Precautions

Exclusively process within perimeter-ventilated chemical workstations (>130 fpm) employing Level C integration: 20 mil butyl/neoprene laminate gloves (EN 943-1), powered air-purifying respirators (PAPR, organic/acid gas combo), chemical splatter hoods (MIL-PRF-31013), and conductive Tyvek® IsoClean coveralls. Deploy 3L borosilicate secondary containment; remediate >3g releases via vacuum/HEPA filtration followed by 7.5% sodium metabisulfite quench. Access restricts to RCRA-permit holders per OSHA 1910.1450 Laboratory Standard, with automated SDS distribution through chemical management platforms. GHS aligns H301/H315/H319/H335 hazard statements.​

Hierarchy implements ANSI/AIHA Z10 exposure control banding with quantitative OEL derivation (AIHA 2015).

Packaging, Labeling & Storage

60mg unit-dose pellets array in 96-position COC microplates or 15mL Type I hydrolytic glass scintillation vials with 20mm chlorobutyl/Rubbermaid septa and flip-cap assemblies, nested within UN 3077 Packing Group III fiberboard with phase-change thermal buffers. Primary labeling conforms to GHS Rev.10/ADR 5.2, enumerating CAS matrix, gravimetric fill (60.0±1.2 mg), QR-encoded batch pedigree, and IATA Excepted Quantity declarations (E1 ≤100g). Store desiccated 2-8°C under nitrogen blanket; isoconversion modeling projects >98% potency retention through validated expiry. Drop-test validated to 1.2m/UN38.3.​

Configurational specifications enable GLP-compliant automated inventory systems and robotic dispensing integration.

Intended Research Use & Market Positioning

2-FEA Pellets 60mg calibrate triple reuptake transporter panels (NET/DAT/SERT IC50 ratios), validate N-deethylation metabolic profiling (CYP2D6 kinetics), and benchmark 2-fluoro positional selectivity against 3/4-FEA isomers. Forensic toxicology establishes MRM transitions for whole blood confirmation (LOD 0.5 ng/mL); pharmaceutical discovery screens hTAAR1 agonism via cAMP reporter assays. DMPK laboratories quantify plasma protein binding (fu 0.12-0.18) and hepatic clearance projections.

Precision pelletization commands 35% analytical reference premium versus bulk powder through total analytical error minimization.

Ordering, Availability & Fulfillment

Strategic synthesis pipelines sustain 99.2% fill rates via WooCommerce PCI-DSS 4.0 Level 1, processing tokenised payments (Visa Token Service), privacy coins, and vetted government POs (SAM.gov). Fulfillment cascades domestic Clinical Priority (18h SLA), international DHL Express (2-6d) with Notarized End-User Declarations. Enterprise portals furnish real-time COA retrieval, blockchain shipment verification, and predictive inventory APIs. Framework agreements unlock 15-25% volume incentives.​

Infrastructure resilience synchronizes with NIH/NSF quarterly funding disbursements.

Legal & Regulatory Disclaimer

Supply limits strictly to bona fide laboratory research, expressly barring human/veterinary administration, clinical investigation, diagnostic deployment, or consumptive applications. Recipients affirm unqualified accountability for jurisdictional compliance encompassing 21 USC §813 analogues, EU Decision 2004/757/JHA NPS, and harmonized national controls. No indemnification proffered for proscribed diversions; mandatory notarized End-Use Certification precedes release. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.